Lead Product(s) : Burixafor
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
TaiGen Partners with GPCR to Develop Burixafor & Taigexyn®
Details : Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide.
Brand Name : TG-0054
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2020
Lead Product(s) : Burixafor
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : GPCR Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?